Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

121. Chronic Kidney Disease. (Abstract)

Chronic Kidney Disease. The definition and classification of chronic kidney disease (CKD) have evolved over time, but current international guidelines define this condition as decreased kidney function shown by glomerular filtration rate (GFR) of less than 60 mL/min per 1·73 m2, or markers of kidney damage, or both, of at least 3 months duration, regardless of the underlying cause. Diabetes and hypertension are the main causes of CKD in all high-income and middle-income countries, and also (...) is measured either via exogenous markers (eg, DTPA, iohexol), or estimated using equations. Presence of proteinuria is associated with increased risk of progression of CKD and death. Kidney biopsy samples can show definitive evidence of CKD, through common changes such as glomerular sclerosis, tubular atrophy, and interstitial fibrosis. Complications include anaemia due to reduced production of erythropoietin by the kidney; reduced red blood cell survival and iron deficiency; and mineral bone disease

2016 Lancet

122. Metabolically Healthy Obesity and Development of Chronic Kidney Disease Full Text available with Trip Pro

Metabolically Healthy Obesity and Development of Chronic Kidney Disease 27842407 2017 12 07 2018 12 02 1539-3704 165 10 2016 11 15 Annals of internal medicine Ann. Intern. Med. Metabolically Healthy Obesity and Development of Chronic Kidney Disease. 743 10.7326/L16-0407 Kahn Henry S HS From Centers for Disease Control and Prevention, Atlanta, Georgia. Pavkov Meda E ME From Centers for Disease Control and Prevention, Atlanta, Georgia. eng CC999999 Intramural CDC HHS United States Journal Article (...) Comment United States Ann Intern Med 0372351 0003-4819 AIM IM Ann Intern Med. 2016 Mar 1;164(5):305-12 26857595 Ann Intern Med. 2016 Nov 15;165(10 ):744-745 27842405 Body Mass Index Humans Obesity Obesity, Metabolically Benign Renal Insufficiency, Chronic 2016 11 15 6 0 2016 11 15 6 0 2017 12 8 6 0 ppublish 27842407 2582915 10.7326/L16-0407 PMC5308792 NIHMS848359 Int J Obes (Lond). 2016 May;40(5):883-6 26841729 PLoS One. 2016 Jan 05;11(1):e0146057 26731527 Ann Intern Med. 2016 Mar 1;164(5):305-12

2016 Annals of Internal Medicine

123. Sarcopenia, Obesity, and Mortality in US Adults With and Without Chronic Kidney Disease Full Text available with Trip Pro

Sarcopenia, Obesity, and Mortality in US Adults With and Without Chronic Kidney Disease In pre-dialysis chronic kidney disease (CKD), the association of muscle mass with mortality is poorly defined, and no study has examined outcomes related to the co-occurrence of low muscle mass and excess adiposity (sarcopenic-obesity). Methods: We examined abnormalities of muscle and fat mass in adult participants of the National Health and Nutrition Examination Survey 1999-2004. We determined whether

2016 Kidney international reports

124. Downregulation of AdipoR1 is Associated with increased Circulating Adiponectin Levels in Serbian Chronic Kidney Disease Patients Full Text available with Trip Pro

Downregulation of AdipoR1 is Associated with increased Circulating Adiponectin Levels in Serbian Chronic Kidney Disease Patients Since the rise in plasma adiponectin levels in chronic kidney disease (CKD) patients has not yet been elucidated, we sought to investigate if patients on hemodialysis (HD) have altered expression of adiponectin receptors in peripheral blood mononuclear cells (PBMCs) compared to healthy subjects.This study included 31 patients with chronic kidney disease on HD and 33

2016 Journal of medical biochemistry

125. Hypertension Control, Apparent Treatment Resistance, and Outcomes in the Elderly Population With Chronic Kidney Disease Full Text available with Trip Pro

Hypertension Control, Apparent Treatment Resistance, and Outcomes in the Elderly Population With Chronic Kidney Disease Chronic kidney disease (CKD) is often associated with poor hypertension control and treatment resistance, but whether CKD modifies the effect of hypertension control on outcomes is unknown.We studied 10-year mortality and cardiovascular events according to hypertension control status and CKD (glomerular filtration rate <60 ml/min/1.73m2) in 4262 community-dwelling individuals

2016 Kidney international reports

126. Tackling the Fallout From Chronic Kidney Disease of Unknown Etiology: Why We Need to Focus on Providing Peritoneal Dialysis in Rural, Low-Resource Settings Full Text available with Trip Pro

Tackling the Fallout From Chronic Kidney Disease of Unknown Etiology: Why We Need to Focus on Providing Peritoneal Dialysis in Rural, Low-Resource Settings 29142936 2018 11 13 2468-0249 2 1 2017 Jan Kidney international reports Kidney Int Rep Tackling the Fallout From Chronic Kidney Disease of Unknown Etiology: Why We Need to Focus on Providing Peritoneal Dialysis in Rural, Low-Resource Settings. 1-4 10.1016/j.ekir.2016.10.004 Nanayakkara Nishanthe N Department of Medicine, Teaching Hospital (...) , Kandy, Sri Lanka. Wazil A W M AWM Department of Medicine, Teaching Hospital, Kandy, Sri Lanka. Gunerathne Lishanthe L Department of Medicine, Renal Care and Research Unit, Girandurukotte, Sri Lanka. Dickowita Sewmini S Department of Medicine, Teaching Hospital, Kandy, Sri Lanka. Rope Robert R Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA. Ratnayake Charaka C Department of Medicine, Teaching Hospital, Kandy, Sri Lanka. Saxena Anjali

2016 Kidney international reports

127. Timely Referral to Outpatient Nephrology Care Slows Progression and Reduces Treatment Costs of Chronic Kidney Diseases Full Text available with Trip Pro

Timely Referral to Outpatient Nephrology Care Slows Progression and Reduces Treatment Costs of Chronic Kidney Diseases We present a new approach to evaluate the importance of ambulatory nephrology care in patients with chronic kidney disease (CKD).An anonymized health claims database of German insurance companies was searched in a retrospective analysis for patients with CKD using the codes of the International Classification of Diseases, 10th German modification. A total of 105,219 patients (...) with CKD were identified. Patients were assigned to the group "timely referral," when nephrology care was present in the starting year 2009, or initiated during the following 3 years in CKD1-4. Using frequency matching for age and gender, 21,024 of the late referral group were matched with the equal number of patients in the timely referral group. Hospital admission rates, total treatment costs, and kidney function (change in CKD stages, start of dialysis, mortality) were documented each year during

2016 Kidney international reports

128. Interventions for chronic kidney disease in people with sickle cell disease. Full Text available with Trip Pro

Interventions for chronic kidney disease in people with sickle cell disease. This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effectiveness of any intervention in preventing or reducing kidney complications or CKD in people with SCD (including red blood cell transfusions, hydroxyurea and ACEI (either alone or in combination with each other)).

2016 Cochrane

129. The Green Tea Polyphenol(—)-epigallocatechin-3-gallate and its beneficial roles in chronic kidney disease Full Text available with Trip Pro

The Green Tea Polyphenol(—)-epigallocatechin-3-gallate and its beneficial roles in chronic kidney disease Chronic kidney disease (CKD), a condition that affects around 10% of the population, has become a significant public health concern. Current therapeutic strategies to slow down the progression of CKD remain limited. Thus, it is urgent to develop new strategies to manage the patients with CKD. Work within the past decade has improved our understanding of the mechanisms contributing to CKD (...) . In particular, oxidative stress as well as inflammation appears to play a pivotal role in CKD progression. ()-Epigallocatechin-3-gallate (EGCG), the major catechin of green tea extract, is known as a powerful antioxidant and reactive oxygen species scavenger. Various studies have shown EGCG has a potential role in chronic kidney disease models. It is suggested that EGCG modulates cellular and molecular mechanisms via inflammation-related NF-кB and Nrf2 signaling pathway, as well as apoptosis-related ER

2016 Journal of translational internal medicine

130. Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness

scenarios involving patients in CKD stages 3 to 5D. In addition, sevelemar is cheaper and more clinically effective than calcium-carbonate in all scenarios involving a subset of pre-dialysis or NDD-CKD patients. Tags kidney, kidney diseases, polyamines, Chronic Renal Disease, Chronic Renal Failure, Sevelamer Files Rapid Response Summary with Critical Appraisal Published : September 21, 2016 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter: (...) Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

131. Depression in Chronic Kidney Disease and End-Stage Renal Disease: Similarities and Differences in Diagnosis, Epidemiology, and Management Full Text available with Trip Pro

Depression in Chronic Kidney Disease and End-Stage Renal Disease: Similarities and Differences in Diagnosis, Epidemiology, and Management Depression is highly prevalent and is associated with poor quality of life and increased mortality among adults with chronic kidney disease (CKD), including those with end-stage renal disease (ESRD). However, there are several important differences in the diagnosis, epidemiology, and management of depression between patients with non-dialysis-dependent CKD

2016 Kidney international reports

132. Evaluation of Renal Blood Flow in Chronic Kidney Disease Using Arterial Spin Labeling Perfusion Magnetic Resonance Imaging Full Text available with Trip Pro

Evaluation of Renal Blood Flow in Chronic Kidney Disease Using Arterial Spin Labeling Perfusion Magnetic Resonance Imaging Chronic kidney disease (CKD) is known to be associated with reduced renal blood flow. However, data to-date in humans is limited.In this study, non-invasive arterial spin labeling (ASL) MRI data was acquired in 33 patients with diabetes and stage-3 CKD, and 30 healthy controls.A significantly lower renal blood flow both in cortex (108.4±36.4 vs. 207.3±41.8; p<0.001, d=2.52 (...) to separate healthy and CKD was estimated to be Cor_BF=142.9 and Med_BF=24.1.These results support the use of ASL in the evaluation of renal blood flow in patients with moderate level of CKD. Whether these measurements can identify subjects at risk of progressive CKD requires further longitudinal follow-up.

2016 Kidney international reports

133. Iron (III) isomaltoside 1000 (Diafer) - iron deficiency in adults with chronic kidney disease (CKD) on dialysis

Iron (III) isomaltoside 1000 (Diafer) - iron deficiency in adults with chronic kidney disease (CKD) on dialysis 1 Published 13 February 2017 Re-submission iron III isomaltoside 1000 (contains 50mg iron per mL) (Diafer ® ), solution for injection SMC No. (1177/16) Pharmacosmos UK Limited 13 January 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in Scotland (...) . The advice is summarised as follows: ADVICE: following a resubmission iron III isomaltoside 1000 5% (Diafer ® ) is accepted for use within NHS Scotland. Indication under review: For the treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used. Iron III isomaltoside 1000 at a higher (10%) concentration has been shown to be non-inferior to another intravenous iron product in maintaining haemoglobin concentration

2016 Scottish Medicines Consortium

134. Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial Full Text available with Trip Pro

Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial The efficacy of folic acid therapy on renal outcomes has not been previously investigated in populations without folic acid fortification.To test whether treatment with enalapril and folic acid is more effective in slowing renal function decline than enalapril alone across a spectrum of renal function at baseline from normal to moderate chronic kidney (...) was the progression of CKD, defined as a decrease in eGFR of 30% or more and to a level of less than 60 mL/min/1.73 m2 if the baseline eGFR was 60 mL/min/1.73 m2 or more, or a decrease in eGFR of 50% or more if the baseline eGFR was less than 60 mL/min/1.73 m2; or end-stage renal disease. Secondary outcomes included a composite of the primary outcome and all-cause death, rapid decline in renal function, and rate of eGFR decline.Overall, 15 104 Chinese adults with a mean (range) age of 60 (45-75) years were

2016 EvidenceUpdates Controlled trial quality: predicted high

135. Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort Full Text available with Trip Pro

Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort Human studies report conflicting results on the predictive power of serum lipids on progression of chronic kidney disease (CKD). We aimed to systematically identify the lipids that predict progression to end-stage kidney disease.From the Chronic Renal Insufficiency Cohort, 79 patients with CKD stage 2 to 3 who progressed to ESKD over 6 years of follow up were selected and frequency-matched

2016 Kidney international reports Controlled trial quality: uncertain

136. Relationship between occult hepatitis B virus infection and chronic kidney disease in a Chinese population-based cohort Full Text available with Trip Pro

Relationship between occult hepatitis B virus infection and chronic kidney disease in a Chinese population-based cohort Previous studies have revealed inconsistent results regarding the association between occult hepatitis B virus (HBV) infection and chronic kidney disease (CKD). Therefore, we conducted a prospective cohort study to evaluate the association between occult HBV infection and CKD.A total of 4329 adults, aged 46.2 ± 13.7 years, without CKD at baseline were enrolled while undergoing (...) physical examinations. Occult HBV infection was defined as seropositivity for antibody to HBV core antigen. CKD was defined as decreased estimated glomerular filtration rate (eGFR < 60 ml·min-1·1.73 m-2) or presence of proteinuria ≥1+, assessed using a repeated dipstick method. eGFR was computed using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.The prevalence of occult HBV infection was 8.1% (352/4329). During 5 years of follow-up, 165 patients (3.8%) developed CKD

2016 Chronic diseases and translational medicine

137. Trends in Prevalence of Chronic Kidney Disease in the United States. Full Text available with Trip Pro

Trends in Prevalence of Chronic Kidney Disease in the United States. Trends in the prevalence of chronic kidney disease (CKD) are important for health care policy and planning.To update trends in CKD prevalence.Repeated cross-sectional study.NHANES (National Health and Nutrition Examination Survey) for 1988 to 1994 and every 2 years from 1999 to 2012.Adults aged 20 years or older.Chronic kidney disease (stages 3 and 4) was defined as an estimated glomerular filtration rate (eGFR) of 15 to 59 mL (...) /min/1.73 m2, estimated with the Chronic Kidney Disease Epidemiology Collaboration equation from calibrated serum creatinine measurements. An expanded definition of CKD also included persons with an eGFR of at least 60 mL/min/1.73 m2 and a 1-time urine albumin-creatinine ratio of at least 30 mg/g.The unadjusted prevalence of stage 3 and 4 CKD increased from the late 1990s to the early 2000s. Since 2003 to 2004, however, the overall prevalence has largely stabilized (for example, 6.9% prevalence

2016 Annals of Internal Medicine

138. Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study Full Text available with Trip Pro

Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study Levels of fibroblast growth factor 23 (FGF23) are elevated in chronic kidney disease (CKD) and strongly associated with left ventricular hypertrophy, heart failure, and death. Whether FGF23 is an independent risk factor for atrial fibrillation in CKD is unknown.To investigate the association of FGF23 with atrial fibrillation in CKD.Prospective cohort (...) study of 3876 individuals with mild to severe CKD who enrolled in the Chronic Renal Insufficiency Cohort Study between June 19, 2003, and September 3, 2008, and were followed up through March 31, 2013.Baseline plasma FGF23 levels.Prevalent and incident atrial fibrillation.The study cohort comprised 3876 participants. Their mean (SD) age was 57.7 (11.0) years, and 44.8% (1736 of 3876) were female. Elevated FGF23 levels were independently associated with increased odds of prevalent atrial fibrillation

2016 JAMA cardiology

139. Implantation of Autologous Selected Renal Cells in Diabetic Chronic Kidney Disease Stages 3 and 4—Clinical Experience of a “First in Human” Study Full Text available with Trip Pro

Implantation of Autologous Selected Renal Cells in Diabetic Chronic Kidney Disease Stages 3 and 4—Clinical Experience of a “First in Human” Study Animal models of chronic kidney disease demonstrate that a redundant population of therapeutically bioactive selected renal cells (SRCs) can be delivered to the kidney through intraparenchymal injection and arrest disease progression. Direct injection of SRCs has been shown to attenuate nuclear factor-κB, which is known to drive tissue (...) inflammation, as well as the transforming growth factor-β-mediated plasminogen activator inhibitor-1 response that drives tissue fibrosis.We present experience from the first-in-human clinical study with SRCs. Seven male type 2 diabetic patients (63 ± 2 years of age) with chronic kidney disease stage 3 to 4 (estimated glomerular filtration rate 25 ± 2 ml/min) were recruited. After blood and urine sampling, iohexol clearance, magnetic resonance imaging, and renal scintigraphy, patients underwent ultrasound

2016 Kidney international reports

140. Grape seed powder improves renal failure of chronic kidney disease patients Full Text available with Trip Pro

Grape seed powder improves renal failure of chronic kidney disease patients Chronic kidney disease (CKD) is a syndrome characterized by progressive and irreversible deterioration of renal function linked to slow destruction of renal parenchyma, eventually terminating in death when sufficient number of nephrons are damaged. Oxidative stress is commonly observed in CKD patients resulting from an imbalance between overproduction of reactive oxygen species (ROS) and impairment of defence mechanisms (...) . Grape seed extract (GSE) is a polyphenolic mixture exhibiting antioxidant and anti-inflammatory properties. We conducted an interventional pilot study of supplementation with GSE capsules (GSE group, n = 23) or placebo (control group, n = 10) on CKD patients. Blood and urine samples were collected at baseline and after a six-month-long supplementation period to determine some renal function biomarkers, as well as antioxidant, anti-inflammatory and haematological parameters. GSE improved glomerular

2016 EXCLI journal Controlled trial quality: uncertain